JP2010509286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509286A5 JP2010509286A5 JP2009535730A JP2009535730A JP2010509286A5 JP 2010509286 A5 JP2010509286 A5 JP 2010509286A5 JP 2009535730 A JP2009535730 A JP 2009535730A JP 2009535730 A JP2009535730 A JP 2009535730A JP 2010509286 A5 JP2010509286 A5 JP 2010509286A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 206010019375 Helicobacter infections Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- -1 1H-benzimidazol-5-yl Chemical group 0.000 claims 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000012639 Balance disease Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037779 Radiculopathy Diseases 0.000 claims 2
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000003210 demyelinating effect Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 201000000312 duodenum cancer Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 230000037149 energy metabolism Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 230000028996 humoral immune response Effects 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 208000006473 polyradiculopathy Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- NITUEMISTORFON-PPFXTMJRSA-N (2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N)C(C)C)C(C)C)C1=CC=CC=C1 NITUEMISTORFON-PPFXTMJRSA-N 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101710144961 Interferon tau-1 Proteins 0.000 claims 1
- 101710144950 Interferon tau-2 Proteins 0.000 claims 1
- 101710144962 Interferon tau-3 Proteins 0.000 claims 1
- 229940123313 MCP-1 antagonist Drugs 0.000 claims 1
- 229940082332 Muscarinic M1 receptor antagonist Drugs 0.000 claims 1
- 108010008881 NBI 5788 Proteins 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100031674 Protein-L-isoaspartate(D-aspartate) O-methyltransferase Human genes 0.000 claims 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 239000002439 beta secretase inhibitor Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108700027921 interferon tau Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000000234 muscarinic M1 receptor antagonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 108010018276 trimethylguanosine synthase Proteins 0.000 claims 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
- IVSZHZVJPWFBLG-UHFFFAOYSA-N CC(C)(c1nnn[n]1-c1ccc(cc[n]2C)c2c1)NCCc1c[nH]c2c1cccc2 Chemical compound CC(C)(c1nnn[n]1-c1ccc(cc[n]2C)c2c1)NCCc1c[nH]c2c1cccc2 IVSZHZVJPWFBLG-UHFFFAOYSA-N 0.000 description 1
- OPCJWUCXGCXOJO-UHFFFAOYSA-N CC(C)C(c1nnn[n]1C1CCCCC1)Nc1ncccc1 Chemical compound CC(C)C(c1nnn[n]1C1CCCCC1)Nc1ncccc1 OPCJWUCXGCXOJO-UHFFFAOYSA-N 0.000 description 1
- YIBITRLQPTYLNG-UHFFFAOYSA-N C[n]1c2cc(-[n]3nnnc3C3(CCCCC3)NCCc3c[nH]c4ccccc34)ccc2cc1 Chemical compound C[n]1c2cc(-[n]3nnnc3C3(CCCCC3)NCCc3c[nH]c4ccccc34)ccc2cc1 YIBITRLQPTYLNG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86499006P | 2006-11-09 | 2006-11-09 | |
| US60/864,990 | 2006-11-09 | ||
| PCT/EP2007/062037 WO2008055950A1 (en) | 2006-11-09 | 2007-11-08 | Novel inhibitors of glutaminyl cyclase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509286A JP2010509286A (ja) | 2010-03-25 |
| JP2010509286A5 true JP2010509286A5 (enExample) | 2011-02-17 |
| JP5599614B2 JP5599614B2 (ja) | 2014-10-01 |
Family
ID=38963183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535730A Expired - Fee Related JP5599614B2 (ja) | 2006-11-09 | 2007-11-08 | グルタミニルシクラーゼの新規阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7741354B2 (enExample) |
| EP (1) | EP2086960B1 (enExample) |
| JP (1) | JP5599614B2 (enExample) |
| DK (1) | DK2086960T3 (enExample) |
| ES (1) | ES2481442T3 (enExample) |
| WO (1) | WO2008055950A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947712B2 (en) * | 2006-08-23 | 2011-05-24 | Wyeth Llc | 8-hydroxyquinoline compounds and methods thereof |
| WO2008110523A1 (en) * | 2007-03-09 | 2008-09-18 | Probiodrug Ag | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
| EP2160380B1 (en) * | 2007-04-18 | 2014-04-02 | Probiodrug AG | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| JP5675341B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体 |
| ES2468551T3 (es) * | 2007-04-18 | 2014-06-16 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa |
| JP5675343B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| EP2142515B1 (en) * | 2007-04-18 | 2014-03-26 | Probiodrug AG | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
| JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| AU2008297070A1 (en) * | 2007-09-12 | 2009-03-19 | Probiodrug Ag | Transgenic mice |
| WO2009090190A1 (en) * | 2008-01-14 | 2009-07-23 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
| KR101706789B1 (ko) | 2008-07-21 | 2017-02-14 | 프로비오드룩 아게 | 진단용 항체 검사법 |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| WO2011076854A1 (en) | 2009-12-22 | 2011-06-30 | Probiodrug Ag | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
| EP2537029A1 (en) | 2010-02-18 | 2012-12-26 | Probiodrug AG | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| ES2540467T3 (es) | 2010-08-19 | 2015-07-09 | Probiodrug Ag | Estructura cristalina de glutaminil ciclasa |
| CN103459421B (zh) | 2011-03-16 | 2017-07-14 | 前体生物药物股份公司 | 诊断性抗体测定 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| KR20210091830A (ko) * | 2013-03-15 | 2021-07-22 | 비보리온 테라퓨틱스 아게 | 신규한 억제제 |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| MX2017017124A (es) * | 2015-07-06 | 2018-03-09 | Gilead Sciences Inc | 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot). |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| KR20210138585A (ko) * | 2019-03-15 | 2021-11-19 | 닛뽕소다 가부시키가이샤 | 복소 고리 화합물 및 농원예용 살균제 |
| TWI915558B (zh) | 2019-06-14 | 2026-02-21 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CA3175541A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| EP4126862B1 (en) | 2020-04-02 | 2025-05-21 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721234A (en) | 1994-12-07 | 1998-02-24 | Warner-Lambert Company | Glutamate receptor antagonists: fused cycloalkylouinoxalinediones |
| US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| EP1620091B1 (en) * | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8338120B2 (en) * | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
| KR20060009902A (ko) * | 2003-05-05 | 2006-02-01 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| AU2004283461B2 (en) | 2003-10-15 | 2010-02-11 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
| US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US7667044B2 (en) * | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| AU2004290499C1 (en) * | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| WO2005075436A2 (en) * | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| WO2008034891A2 (en) * | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
| ATE554085T1 (de) * | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
-
2007
- 2007-11-08 JP JP2009535730A patent/JP5599614B2/ja not_active Expired - Fee Related
- 2007-11-08 DK DK07822341.9T patent/DK2086960T3/da active
- 2007-11-08 WO PCT/EP2007/062037 patent/WO2008055950A1/en not_active Ceased
- 2007-11-08 ES ES07822341.9T patent/ES2481442T3/es active Active
- 2007-11-08 EP EP07822341.9A patent/EP2086960B1/en active Active
- 2007-11-08 US US11/937,159 patent/US7741354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509284A5 (enExample) | ||
| JP2010509285A5 (enExample) | ||
| JP2010511013A5 (enExample) | ||
| JP2010524895A5 (enExample) | ||
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| JP2010520869A5 (enExample) | ||
| JP2010524898A5 (enExample) | ||
| JP6436205B2 (ja) | キノリン誘導体 | |
| JP2010524893A5 (enExample) | ||
| JP2010524899A5 (enExample) | ||
| JP2013504544A5 (enExample) | ||
| ES2957692T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| JP2010524896A5 (enExample) | ||
| JP2013521325A5 (enExample) | ||
| KR20170106452A (ko) | 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체 | |
| JP2013521260A5 (enExample) | ||
| US20210346377A1 (en) | Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals | |
| JPWO2016104617A1 (ja) | キノリン誘導体 | |
| JP2014508184A5 (enExample) | ||
| JP2014533699A5 (enExample) | ||
| WO2005007651A1 (ja) | ２-アシルアミノチアゾール誘導体又はその塩 | |
| JP3555620B2 (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP2007504128A5 (enExample) | ||
| JP2013525334A5 (enExample) | ||
| JP2018520167A (ja) | ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物 |